ArticleFrontiers in pharmacology2026
Ursolic acid mitigates hepatic ischemia-reperfusion injury by regulating the ALOX12/12(S)-HETE and PTGES/prostaglandin E2 axis via arachidonic acid metabolism pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatic ischemia-reperfusion injury (HIRI) is a critical contributor to poor prognosis after hepatobiliary surgery, yet effective therapeutic strategies remain limited. Ursolic acid (UA), a natural pentacyclic triterpenoid, has shown potential hepatoprotective properties, but its specific mechanism in alleviating HIRI remains unclear. This study aimed to investigate the therapeutic effect of UA on HIRI and elucidate its underlying molecular mechanisms, addressing the clinical need for targeted interventions. Methods: A murine HIRI model was established, and UA was administered to assess its impact on liver function. Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured to evaluate hepatoprotection. Integrated network pharmacology and non-targeted metabolomics were employed to identify key pathways and metabolites involved in UA-mediated protection. Molecular docking was used to predict interactions between UA and target proteins. Experimental validation included assessment of the ALOX12/12(S)-HETE and PTGES/prostaglandin E2 axes. A cellular thermal shift assay (CETSA) was performed to confirm direct binding between UA and the PTGES protein. Results: UA administration significantly reduced serum AST and ALT levels in HIRI mice, confirming its protective role against liver injury. Integrated multi-omics analysis revealed the arachidonic acid metabolic pathway as a central hub for UA's protective effects. Key metabolites (prostaglandin H2 and prostaglandin E2) were markedly downregulated by UA, and UA downregulated the ALOX12/12(S)-HETE and PTGES/prostaglandin E2 axes. CETSA confirmed that UA directly binds to the PTGES protein, supporting its role as a target of UA. Conclusion: UA attenuates HIRI primarily by modulating the arachidonic acid metabolic pathway and inhibiting the ALOX12 and PTGES signaling axes. These findings highlight UA as a promising therapeutic agent for HIRI, with potential for clinical translation to improve outcomes in hepatobiliary surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.